(CRIS) Curis, Inc. Porters Five Forces Research

Curis’s licensing model makes suppliers strong when they control key IP in partnered programs. If a partner owns the science, Curis has less room to push back on royalty, milestone, or sublicense terms, so economics can stay tilted toward the supplier. That risk is highest in collaborative development, where access to know-how can shape both cash burn and deal timing.

• Partner IP can set pricing power.
• Royalty terms are hard to reset.
• Milestones can drain future cash.

Curis, Inc.'s supplier power stays high because it buys in small clinical lots, so vendors face little volume risk and have weak reason to cut prices. In clinical-stage biotech, terms are often tied to project risk, timeline, and data milestones, not long-term scale. That keeps Curis's bargaining leverage low until pipeline spend scales up.

• Small orders limit discount power
• Terms reflect trial risk, not volume
• Scale-up is needed to shift leverage

Curis, Inc. has no broad commercial portfolio yet, so customer power is still indirect in FY2025. That said, any future launch would likely face a small buyer set: major payers, hospitals, and specialty pharmacies, which can press hard on price and access. With no product revenue reported, buyer leverage is now more about future market access than current sales.

• Few buyers, strong pricing pressure
• No broad commercial base yet
• Future sales may face payer control

When Curis, Inc. out-licenses or co-develops assets, bigger pharma partners can push hard on terms. In 2025, Curis still depended on external capital, so its need for cash can weaken its hand and lead to lower royalties, tighter control rights, and stronger exit clauses. In practice, one asset can carry a 10% to 20% royalty ask, but the larger partner often sets the leverage.

• Big pharma can set deal terms.
• Royalty rates may get compressed.
• Control rights can shift away.
• Funding need weakens Curis’s stance.

Curis, Inc. still sits mostly in clinical-stage assets, so it lacks the commercial moat that comes with an approved drug, sales force, and payer access. In oncology, dozens of firms can chase the same pathways, so rivalry is intense before launch and switching costs stay near zero. That is why the key fight is for data, speed, and trial progress, not market share.

• Clinical-stage assets mean low entry barriers.
• Many firms can target the same biology.
• Approval is what creates durable rivalry gaps.
• Pre-launch competition centers on trial data.

Curis, Inc. faces rivals with support from large pharma, venture capital, and strategic partners, and that money often funds wider trial networks and faster site builds. In 2025, that funding edge matters because patient enrollment and investigator access can decide whether a program advances or stalls.

For Curis, the fight is not just science; it is also capital, speed, and visibility. Better-funded programs can spend more on clinical execution and investor outreach, so Curis has to win attention with sharper data and tighter execution.

• Backed rivals move faster in trials.
• More cash helps recruit patients.
• Partner networks widen investigator reach.
• Investor attention often follows funding.

Clinical trial protocol substitution is high for Curis, Inc. in late-stage oncology, because investigators often pick rival studies when they offer faster enrollment, clearer endpoints, or stronger sponsor support. In cancers with very small eligible pools, trial competition itself becomes a substitute, and even a few lost patients can slow data readout and hurt Curis, Inc.'s positioning.

That matters more when enrollment is tight: if a site can screen only a handful of qualified patients, one competitor can drain the pool. For Curis, Inc., slower enrollment can delay milestones, raise trial costs, and reduce the odds of clean efficacy data.

• Rival trials can pull investigators away.
• Rare cancers create scarce patient pools.
• Lost enrollment delays data generation.
• Slower reads weaken Curis, Inc.'s leverage.

Supportive care and watchful waiting can blunt demand for Curis, Inc.’s drugs when doctors can safely delay treatment, especially in indolent cancers that move slowly for months or years. In these settings, observation plus symptom control is a real substitute for immediate therapy, so the new candidate must clear a higher bar on speed, tolerability, or depth of response. The risk is lower in aggressive cancers, but it still matters in selected indications where 20%+ of patients may not need instant escalation.

• Watchful waiting can delay drug start.
• Indolent disease raises substitution risk.
• Aggressive cancers lower, not remove, risk.

Curis, Inc. faces a high threat of new entrants because patents, 20-year patent terms, and FDA exclusivity can block quick imitation. In oncology, new entrants often must buy licenses or design around protected assets, which raises cost and slows launch. Orphan drug exclusivity can last 7 years, and U.S. data exclusivity can run 5 to 12 years, making entry harder.

• Patents delay copycats.
• Licenses add cost and time.
• Exclusivity protects market access.
• Building around IP is slow.

New entrants face a high bar because biotech competition depends on CRO access, academic science, and pharma tie-ups, all of which take years to build. Curis, Inc. already has those links, which makes it harder for a new firm to win trust and move programs fast. That gap gives Curis a real defensive edge against newcomers.

• Partnerships take years to secure
• Established firms get first calls
• Curis has built-in collaborator access